Update on review of valsartan medicines
Risk from NDMA remains low, a related substance NDEA also being investigated
The European Medicines Agency (EMA) has updated its calculation of the risk from valsartan medicines containing N‑nitrosodimethylamine (NDMA), taking into account results from latest tests on the active substance from Zhejiang Huahai.
In line with EMA’s previous assessment, the life-time risk of cancer is considered low and is estimated to be in the order of 1 in 5,000 for an adult patient who had taken an affected valsartan medicine at the highest dose (320 mg) every day from July 2012 to July 2018.
EMA’s risk assessment is based on the average levels of NDMA in the active substanceproduced by Zhejiang Huahai since 2012 (when the company changed its manufacturing process) and on the assumption that all the NDMA is transferred to the final product.
Patients who have taken treatments with lower doses or for shorter lengths of time will be at a lower risk. The risk will also be lower for patients who have taken valsartan produced by Zhejiang Tianyu, which had smaller amounts of NDMA than valsartan produced by Zhejiang Huahai.
The low risk estimate is to some extent supported by a Danish study1 which tracked patients who had taken medicines containing valsartan from Zhejiang Huahai over the past 6 years. However, the authors note that patients were followed up for a relatively short period (4.6 years on average).
In addition to NDMA, EMA is assessing the impact of a related substance, N‑nitrosodiethylamine (NDEA), which has been detected in valsartan made by Zhejiang Huahai using its previous manufacturing process before changes were introduced in 2012. Both NDEA and NDMA belong to the class of nitrosamines and are classified as probable human carcinogens (substances that could cause cancer).
Data on levels of NDEA are currently very limited, and EMA will provide further information on whether its presence impacts the risk assessment once more information becomes available.
Although the review covers all valsartan medicines, the immediate focus has been on medicines containing the active substance manufactured by Zhejiang Huahai and Zhejiang Tianyu where unacceptable levels of NDMA have been confirmed. EU authorities have now carried out inspections of the manufacturing sites of both companies in China and will consider the findings.
Medicines containing valsartan from Zhejiang Huahai and Zhejiang Tianyu are no longer being distributed in the EU or have been recalled. Both companies are not currently authorised to produce valsartan for medicines in the EU.
EMA continues to work closely with national authorities, international partners and EDQM to gather the necessary information which would allow the Agency to have a better understanding of why impurities were present in the active substance in the first place.
Based on the final outcome of the review, authorities in the EU will take necessary measures to ensure that similar problems do not occur in future.
More about the medicine
Valsartan is an angiotensin-II-receptor antagonist used to treat hypertension (high blood pressure), recent heart attack and heart failure. It is available on its own or in combination with other active substances.
Medicines containing valsartan as the only active substance have been authorised in the EU via national authorities. Nine products containing valsartan in combination with other active substances have been authorised centrally via EMA.
More about the procedure
The review of valsartan medicines was triggered by the European Commission on 5 July 2018 under Article 31 of Directive 2001/83/EC.
The review is being carried out by EMA’s Committee for Medicinal Products for Human Use (CHMP), responsible for questions concerning medicines for human use, which will adopt the Agency’s opinion. The CHMP opinion will then be forwarded to the European Commission, which will issue a final legally binding decision applicable in all EU Member States.
1 Pottegard A, Kristensen K, Ernst MT, Johansen NB, Quartorolo P, Hallas J. Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer: Danish nationwide cohort study. BMJ 2018;362:k3851
|Update on review of valsartan medicines||(English only)||13/09/2018|
Latest News from
NextGenerationEU: European Commission disburses €237 million in pre-financing to Latvia13/09/2021 10:25:00
The European Commission recently (10 September 2021) disbursed €237 million to Latvia in pre-financing, equivalent to 13% of the country's financial contribution as established in the Council Implementing Decision.
COVID-19: Council adds Uruguay and removes six countries from the list of countries for which travel restrictions should be lifted10/09/2021 15:25:00
Following a review under the recommendation on the gradual lifting of the temporary restrictions on non-essential travel into the EU, the Council updated the list of countries, special administrative regions and other entities and territorial authorities for which travel restrictions should be lifted.
Strengthened EU export control rules kick in10/09/2021 13:25:00
The EU is strengthening its ability to respond to new security risks and emerging technologies.
NextGenerationEU: European Commission disburses €157 million in pre-financing to Cyprus10/09/2021 11:33:00
The European Commission yesterday disbursed €157 million to Cyprus in pre-financing, equivalent to 13% of the grant and loan component of the country's financial allocation.
2021 Strategic Foresight Report: Enhancing the EU's long-term capacity and freedom to act10/09/2021 09:25:00
The Commission recently (08 September 2021) adopted its second annual Strategic Foresight Report – “The EU's capacity and freedom to act”*.
EU reinforces its leading position in global agri-food trade09/09/2021 16:33:00
2020 marked another improvement in the EU's leading position among the world's biggest exporters of agri-food products. On the import side, the EU has become the third largest importer after the United States and China, according to a report published yesterday.
European Citizens' Initiative: Commission decides to register new citizens' initiative09/09/2021 15:25:00
The European Commission yesterday decided to register a European Citizens' Initiative entitled ‘Ensuring Common Commercial Policy conformity with EU Treaties and compliance with international law'.
Council gives final go-ahead to seven-year funding for accession partners09/09/2021 13:25:00
Member states yesterday gave the final green light to almost 14.2 billion euro of pre-accession financial assistance for the period 2021–2027 in favour of the Republic of Albania, Bosnia and Herzegovina, Kosovo*, Montenegro, the Republic of North Macedonia, the Republic of Serbia and the Republic of Turkey.